当前位置:Public Access >页面
Chinese/English
Efficacy and safety of paclitaxel (albumin-binding) combined with carboplatin for neoadjuvant therapy for unresectable ovarian cancer in women: a single-center, open, one-arm, phase Ib, and phase II clinical study

ChiCTR注册号:

Reg No. in ChiCTR:

研究题目:

Efficacy and safety of paclitaxel (albumin-binding) combined with carboplatin for neoadjuvant therapy for unresectable ovarian cancer in women: a single-center, open, one-arm, phase Ib, and phase II clinical study

Study title:

Efficacy and safety of paclitaxel (albumin-binding) combined with carboplatin for neoadjuvant therapy for unresectable ovarian cancer in women: a single-center, open, one-arm, phase Ib, and phase II clinical study

 注册状况:

 Registration:

False

注册机构:

中国临床试验注册中心

Name of the Registry:

Chinese Clinical Trial Registry

项目负责人:

中国临床试验注册中心

Corresponding person:

Chinese Clinical Trial Registry

电话:

Telephone:

+021-64175590-86632

电子邮件

Email

yanghuijuanfudan@163.com

通讯地址:

复旦大学附属肿瘤医院

Address:

Fudan University Shanghai Cancer Center

邮政编码

Postcode

200032

项目负责人所有单位:

复旦大学附属肿瘤医院

Institution:

Fudan University Shanghai Cancer Center

批准本研究的伦理委员会名称:

复旦大学附属肿瘤医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tumor Hospital Affilia

研究疾病:

卵巢癌

Study Ailment:

ovarian cancer

研究所处阶段:

Study phase:

Post-market

研究类型:

Type of Study:

Therapy Study

研究团队:

Research team:

研究实施地点:

Site of Study:

国家(地区):

中国

省(直辖市):

上海

市(区县):

Country/Area:

China

Province:

Shanghai

City:

单位 复旦大学附属肿瘤医院
Institution Fudan University Shanghai Cancer Center

预计起止时间:

Planned Duration:

2019/11/26 0:00:00-2020/12/30 0:00:00